FX.co ★ Beam Therapeutics To Start Clinical Study Of BEAM-302 In Alpha-1 Antitrypsin Deficiency In UK

Beam Therapeutics Inc. announced on Tuesday that the United Kingdom's Medicines and Healthcare Products Regulatory Agency has approved the company's Clinical Trial Authorization (CTA) application for BEAM-302. This approval pertains to the treatment of patients suffering from Alpha-1 Antitrypsin Deficiency (AATD).

AATD is a genetic condition passed through inheritance, it can lead to severe lung and liver diseases. Beam Therapeutics also disclosed its plans to commence a Phase 1/2 study of BEAM-302. This study, targeted at patients with AATD-linked lung diseases, is set to kick off in the first half of 2024.